Brigatinib

Brigatinib is a medication used to treat certain types of lung cancer, specifically non-small cell lung cancer with specific genetic changes called ALK or ROS1 mutations. It works by blocking abnormal proteins produced by these mutations, which helps stop the cancer cells from growing and spreading. Brigatinib is usually prescribed when previous treatments have not been effective. It is taken orally in the form of tablets and is closely monitored by healthcare providers to manage potential side effects. Overall, it offers a targeted approach to control cancer growth in patients with these specific genetic features.